Evidence map›Paper›PMID 42397036›Full record

ArticleCancer immunology research2026

Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity.

Daisuke Ehara, Kiyoshi Yasui, Mitsuhiro Yoneda, Daisuke Muraoka, Situo Deng, Pengyu Miao, Chenxu Jiang, Huimin Sun, Sachiko Okamoto, Yasunori Amaishi and 2 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daisuke EharaDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0009-0003-0105-2996
Kiyoshi YasuiDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0002-7572-7445
Mitsuhiro YonedaDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0001-6340-1205
Daisuke MuraokaDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0002-4493-7052
Situo DengDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0009-0000-9481-4715
Pengyu MiaoDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0009-0004-2924-4524
Chenxu JiangDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0009-0000-0370-8635
Huimin SunDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0009-0005-6643-5247
Sachiko OkamotoTakara Bio Inc., Kusatsu, Japan.ORCID 0009-0005-4483-3826
Yasunori AmaishiTakara Bio Inc., Kusatsu, Japan.ORCID 0009-0007-7713-6888
Hiroyuki MurotaDepartment of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0002-0450-1377
Hiroaki IkedaDepartment of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0002-8012-4796

Funding

Takara Bio (Takara)The Japan Society for the Promotion of Science 21H02990
6 · The paper itself

Abstract

Tumor masses often exhibit heterogeneity, including escape variant clones that lack antigen-presenting machinery and/or tumor antigens, which poses a major challenge to immunotherapy. Ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, has been shown to effectively induce cell death in various tumor cells. Recent studies have reported that IFNγ suppresses the expression of system Xc-, thereby enhancing the induction of ferroptosis. Based on this, we hypothesized that combining immunotherapy with ferroptosis inducers could enhance antitumor effects against both antigen-positive and antigen-negative tumor cells. We found that combining RSL3, a ferroptosis inducer, with MART-1-specific T-cell receptor-engineered T cells eradicates a heterogeneous tumor model consisting of human melanoma cells and their β2-microglobulin knockout counterparts. In NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic mice, this combination therapy demonstrates a significant antitumor effect against tumors with heterogeneity. These findings suggest that integrating ferroptosis inducers with immunotherapy could overcome the limitations imposed by escape-variant tumor clones, offering a promising strategy for cancer treatment.

Indexed as

FerroptosisInterferon-gammaMelanomaT-LymphocytesTumor EscapeAnimalsCell Line, TumorHumansImmunotherapyMiceMice, Inbred NODInterferon-gamma

Identifiers

PMID42397036
PMCPMC13535315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.